ACT	Atypical cartilaginous tumor
CBR	clinical benefit rate
ChS	Chondrosarcoma
CR	Complete response
CSC	Cancer stem cell
CSF1R	Colony stimulating factor 1 receptor
CSPG4	ProteoGlycan 4
DCR	Disease control rate
ddChS Dedifferentiated ChS
DFS	Disease-free survival
DoR	Duration of response
ECM	Extracellular matrix
HDAC	Histone deacetylase
HIF	Hypoxia-inducible factor
ICI	Immune checkpoint inhibitor
IHC	Immunohistochemistry
IL	Interleukin
LOX	Lysyl oxidase
Matrix metalloproteinases
MTD	Maximum tolerated dose
mTOR	Mammalian target of rapamycin
OR	Objective response
ORR	Overall response rate
OS	Overall survival
PD	Progressive disease
PDGF	Platelet-derived growth factor
PFS	Progression-free survival
PFSR	Progression-free survival rate
PR	Partial response
RFS	Relapse-free survival
RR	Response rate
SD	Stable disease
TAMs	Tumor-associated macrophages
TANs	Tumor-associated neutrophils
TME	Tumor microenvironment
Human umbilical vein endothelial cells
VEGF	Vascular endothelial growth factor